The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of EZN-2208 (PEG-SN38) with or without cetuximab in patients with metastatic colorectal cancer (CRC).
Richard M. Goldberg
Consultant or Advisory Role - Amgen; Genentech; Lilly; MedImmune
Research Funding - Bayer; Enzon; Sanofi
Chris R. Garrett
No relevant relationships to disclose
Noah C. Berkowitz
Employment or Leadership Position - Enzon
Stock Ownership - Enzon
Tanios S. Bekaii-Saab
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Genentech
Honoraria - Amgen; Bristol-Myers Squibb; Genentech
Theresa Ryan
No relevant relationships to disclose
George A. Fisher
No relevant relationships to disclose
Sally Clive
No relevant relationships to disclose
Petr Kavan
No relevant relationships to disclose
Einat Shmueli
No relevant relationships to disclose
Aby Buchbinder
Employment or Leadership Position - Enzon
Stock Ownership - Enzon